Literature DB >> 6155270

Chemical properties and tumor affinity of separated isomers of cobalt-bleomycin.

J Kakinuma, R Kagiyama, H Orii.   

Abstract

Co-57 bleomycin is a chemically stable and diagnostically useful radiopharmaceutical. Stoichiometric preparation of Co-bleomycin causes two chemically different complexes. Four kinds of chelates (A2- type I, A2-type II, B2-type I and B2-type II) are easily separated by silicagel then-layer chromatography. Circular dicroism study of these chelates indicate that two types of complexes are conformational isomers. This chemical difference is assumed to cause the difference in the biological behavior. The biodistribution study of each type of complex, using tumor-bearing mice, showed higher tumor-to-blood ratios and tumor-to muscle ratios as compared with the clinical grade Co-bleomycin mixture. But the difference between the two types was not as large as expected. The similarity in biologic bahavior suggests that the groups on the bleomycin molecule, which are concerned with chelate formation, do not take part in its binding to DNA.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155270     DOI: 10.1007/BF00252478

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  10 in total

1.  Use of radioactive bleomycin to detect malignant intracranial tumors. Comparative study with technetium-99m in 104 cases.

Authors:  L Mamo; J P Nouel; J Robert; N Chai; R Houdart
Journal:  J Neurosurg       Date:  1973-12       Impact factor: 5.115

2.  A reaction of cobalt bleomycin with dissolved oxygen.

Authors:  A D Nunn
Journal:  Int J Nucl Med Biol       Date:  1977-12

3.  Studies of tumor metabolism--II. Mössbauer spectroscopy of 57Co-bleomycin.

Authors:  M R Zalutsky; A M Friedman; J C Sullivan; S L Ruby; G V Rayudu
Journal:  Int J Nucl Med Biol       Date:  1977-12

4.  Purification of bleomycins.

Authors:  H Umezawa; Y Suhara; T Takita; K Maeda
Journal:  J Antibiot (Tokyo)       Date:  1966-09       Impact factor: 2.649

5.  Chemical and biologic properties of isolated radiolabeled bleomycin preparations.

Authors:  W C Eckelman; W J Rzeszotarski; B A Siegel; H Kubota; M Chelliah; J Stevenson; R C Rebra
Journal:  J Nucl Med       Date:  1975-11       Impact factor: 10.057

6.  Clinical evaluation of radiolabeled bleomycin (BLEO) for tumor detection.

Authors:  R B Grove; R C Reba; W C Eckelman; M Goodyear
Journal:  J Nucl Med       Date:  1974-06       Impact factor: 10.057

7.  Binding of bleomycin to DNA: intercalation of the bithiazole rings.

Authors:  L F Povirk; M Hogan; N Dattagupta
Journal:  Biochemistry       Date:  1979-01-09       Impact factor: 3.162

8.  Transition-metal binding site of bleomycin A2. A carbon-13 nuclear magnetic resonance study of the zinc(II) and copper(II) derivatives.

Authors:  J C Dabrowiak; F T Greenaway; R Grulich
Journal:  Biochemistry       Date:  1978-09-19       Impact factor: 3.162

9.  Bleomycin-DNA interactions: fluorescence and proton magnetic resonance studies.

Authors:  M Chien; A P Grollman; S B Horwitz
Journal:  Biochemistry       Date:  1977-08-09       Impact factor: 3.162

10.  A spectroscopic investigation of the metal binding site of bleomycin A2. The Cu(II) and Zn(II) derivatives.

Authors:  J C Dabrowiak; F T Greenaway; W E Longo; M Van Husen; S T Crooke
Journal:  Biochim Biophys Acta       Date:  1978-02-16
  10 in total
  2 in total

1.  Labelled bleomycin as a tumour-localizing agent. II. The effect of dose loading of the different forms of 57Cobalt-bleomycin A2, B2, and pepleomycin on the tissue distribution and tumour uptake in tumour-bearing rats.

Authors:  C M Vos; G Westera
Journal:  Eur J Nucl Med       Date:  1982

2.  Stability of 111In-bleomycin in vivo--properties compared with 57Co-bleomycin.

Authors:  D Y Hou; H Hoch; G S Johnston; K C Tsou; R J Farkas; E E Miller
Journal:  Eur J Nucl Med       Date:  1983
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.